References
Zádori D, Veres G, Szalárdy L, Klivényi P, Vécsei L (2015) Drug-induced movement disorders. Expert Opin Drug Saf 14(6):877–890
Chen JJ (2012) Drug-induced movement disorders. Mental Health Clin 1(7):167–173
Teive HA, Munhoz RP, Ferraz HB (2009) Flunarizine and cinnarizine-induced Parkinsonism: 25 years of de Melo-Souza’s syndrome. Arq Neuropsiquiatr 67(3B):957
Teive HAG, Troiano AR, Germiniani FMB, Werneck LC (2004) Flunarizine and cinnarizine-induced Parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord 10:243–245
Martin RJ (2004) Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry 75:iii22–iii28
Pedro-Botet ML, Bonal J, Caralps A (1989) Nifedipine and myoclonic disorders. Nephron 51:281
Dressler D (2014) Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. J Neural Transm 121:367–369
Wallace EL, Lingle K, Pierce D, Satko S (2009) Amlodipine-induced myoclonus. Am J Med 122:e7
Munhoz RP, Bertucci FD, Teive HAG (2017) Not all drug-induced Parkinsonism are the same: the effect of drug class on motor phenotype. Neurol Sci 38:319–324
Abdo WF, Van De Warrenburg BP, Burn DJ, Quinn NP, Bloem BR (2010) The clinical approach to movement disorders. Nat Rev Neurol 6:29–37
Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R (1997) Brain pharmacokinetics and in vivo receptor binding of 1, 4-dihydropyridine calcium channel antagonists. Life Sci 61:2083–2090
Surmeier DJ (2009) A lethal convergence of dopamine and calcium. Neuron 62:163–164
Swart T, Hurley MJ (2016) Calcium channel antagonists as disease-modifying therapy for Parkinson’s disease: therapeutic rationale and current status. CNS Drugs 30:1127–1135
Funding
Elderly Pharmacovigilance Programme has funding support from the National Programme for Healthcare of the Elderly, Ministry of Health and Family Welfare, Government of India.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Elderly Pharmacovigilance Programme has the institutional ethics committee approval no. Dean/2015-16/IEC/411.
Informed consent
Written informed consent was taken from patient’s legal guardian (son) for publication of case and videos.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Kaur, U., Das, P., Gambhir, I.S. et al. L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza’s syndrome. Neurol Sci 40, 1077–1080 (2019). https://doi.org/10.1007/s10072-018-3662-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-018-3662-1